Minimally Invasive and Novel Therapeutics (MINT)

September 8-10, 2024

Fairmont Copley Plaza, Boston
138 St. James Avenue, Boston, MA 02116

Hybrid Course (offered In-person or online) &
optional hands on sessions

Course Directors:
Charudutt Paranjape, MD, MBBS, FACS
Kumar Krishnan, MD

Current treatment strategies for patients with complex digestive disorders continue to evolve. This is largely the result of growing technological advances in surgery and endoscopy.

The goal of the Minimally Invasive and Novel Therapeutics (MINT) course is to inform physicians on how best to incorporate these technologies into their practice. Using a video-based format, our goal is technique transfer from world-renowned faculty to the community, hospital, endoscopy suite, and operating room.

MINT offers an ideal mix of traditional standard-of-care principles with a balanced and unbiased view of new, cutting-edge information. This hybrid course (in-person and virtual) engages learners through video-based lectures with recordings of surgical and endoluminal therapies, along with lively multidisciplinary panel discussions, and hands-on training sessions in both endoluminal therapies and surgical techniques.

The annual hybrid Minimally Invasive and Novel Therapeutics (MINT) continuing medical education (CME) course, seeks to equip clinicians with advanced technical knowledge of the latest surgical and endoscopic procedures needed to diagnose and treat foregut disease utilizing novel educational formats such as video-based learning to encourage “technique transfer”.

We further hope to foster ongoing collaboration between gastroenterologists, surgeons, advanced practice providers, nurses, and dietitians to optimize the multidisciplinary care of patients with foregut digestive disease.

The annual conference is both in-person, with an optional hands-on component, and virtual live-streamed (and recorded).

Highlights for MINT 2024 include:

  • Foregut disease
  • Endoluminal/ flexible endoscopy Hands-on
  • Robotic Hands-on
  • Resident Robotic surgery hands-on and didactics
  • Bariatric
  • Pancreaticobiliary
  • Hernia and abdominal wall
  • MINT Multidisciplinary Team session

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Apply new knowledge in the management of patients with foregut disease, abdominal wall hernias, and pancreaticobiliary disease
  • Develop treatment strategies based on current evidence and expert opinion
  • Compare and contrast standard-of-care management with cutting-edge treatments
  • Recognize the unique roles and contributions of various healthcare professionals within the multidisciplinary foregut team
  • Collaborate effectively among multidisciplinary team members to improve patient outcomes

Who should attend:
Provider type: General surgeons, thoracic surgeons, gastroenterologists, nurse practitioners, physician assistants, nurses, dietitians

The Harvard Medical School designates this hybrid course for a maximum of 22.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity

Nursing Accreditation
Harvard Medical School designates this live activity for a maximum of 22.25 ANCC contact hours.